Skip to Content
Merck

Y0001493

Furosemide for peak identification

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Furosemide, 4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid, 5-(Aminosulfonyl)-4-chloro-2-([2-furanylmethyl]amino)benzoic acid

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C12H11ClN2O5S
CAS Number:
54-31-9
Molecular Weight:
330.74
NACRES:
NA.24
PubChem Substance ID:
329831456
UNSPSC Code:
41116107
MDL number:
MFCD00010549

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Furosemide for peak identification, European Pharmacopoeia (EP) Reference Standard

InChI

1S/C12H11ClN2O5S/c13-9-5-10(15-6-7-2-1-3-20-7)8(12(16)17)4-11(9)21(14,18)19/h1-5,15H,6H2,(H,16,17)(H2,14,18,19)

SMILES string

NS(=O)(=O)c1cc(C(O)=O)c(NCc2ccco2)cc1Cl

InChI key

ZZUFCTLCJUWOSV-UHFFFAOYSA-N

grade

pharmaceutical primary standard

API family

furosemide

manufacturer/tradename

EDQM

mp

220 °C (dec.) (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

Gene Information

human ... SLC12A1(6557)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Application

Furosemide for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Inhibits ion co-transport in the kidney.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Danger

Hazard Classifications

Acute Tox. 4 Oral - Repr. 1B

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

K M Ho et al.
Anaesthesia, 65(3), 283-293 (2010-01-21)
Furosemide, a potent loop diuretic, is frequently used in different stages of acute kidney injury, but its clinical roles remain uncertain. This review summarises the pharmacology of furosemide, its potential uses and side effects, and the evidence of its efficacy.
Kurt A Wargo et al.
The Annals of pharmacotherapy, 43(11), 1836-1847 (2009-10-22)
To review the literature regarding the pharmacokinetic profiles, comparative safety and efficacy, and comparative costs of loop diuretics to evaluate the current clinical usefulness of furosemide. A search of MEDLINE (1966-June 2009) was conducted using the terms furosemide, torsemide, bumetanide
Phillip J Newton et al.
Journal of pain and symptom management, 36(4), 424-441 (2008-05-13)
Dyspnea is a common and distressing symptom associated with multiple chronic illnesses and high levels of burden for individuals, their families and health care systems. The subjective nature dyspnea and a poor understanding of pathophysiological mechanisms challenge the clinician in
Christianne L Roumie et al.
Stroke, 46(2), 465-470 (2015-01-01)
We examined blood pressure 1 year after stroke discharge and its association with treatment intensification. We examined the systolic blood pressure (SBP) stratified by discharge SBP (≤140, 141-160, or >160 mm Hg) among a national cohort of Veterans discharged after
Adam D DeVore et al.
European journal of heart failure, 17(3), 340-346 (2015-01-27)
Loop diuretics are a cornerstone of heart failure (HF) treatment, but data regarding diuretic dose adjustments after a HF hospitalization and the association with subsequent outcomes are limited. This study was therefore conducted to determine these factors. We analysed data
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service